Welch & Forbes LLC reduced its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 1.9% during the first quarter, according to its most recent filing with the SEC. The fund owned 657,528 shares of the company’s stock after selling 12,566 shares during the quarter. Johnson & Johnson accounts for approximately 2.1% of Welch & Forbes LLC’s portfolio, making the stock its 11th largest holding. Welch & Forbes LLC’s holdings in Johnson & Johnson were worth $160,726,000 as of its most recent SEC filing.
Other institutional investors also recently added to or reduced their stakes in the company. Blueline Advisors LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at about $25,000. Cresta Advisors Ltd. purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $26,000. DecisionPoint Financial LLC increased its stake in shares of Johnson & Johnson by 104.2% during the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after purchasing an additional 75 shares during the last quarter. Family CFO Inc bought a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $31,000. Finally, Bay Harbor Wealth Management LLC lifted its stake in Johnson & Johnson by 49.0% in the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after purchasing an additional 49 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.
Insider Buying and Selling
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. The trade was a 8.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is currently owned by corporate insiders.
Johnson & Johnson Trading Up 0.3%
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. During the same period last year, the company earned $2.77 earnings per share. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. As a group, analysts anticipate that Johnson & Johnson will post 11.58 earnings per share for the current year.
Wall Street Analysts Forecast Growth
JNJ has been the subject of several research reports. JPMorgan Chase & Co. increased their price objective on Johnson & Johnson from $250.00 to $260.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Royal Bank Of Canada upped their price target on Johnson & Johnson from $265.00 to $287.00 and gave the company an “outperform” rating in a research report on Monday. Leerink Partners upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price target for the company in a research note on Wednesday, May 13th. Johnson Rice set a $270.00 price objective on Johnson & Johnson in a report on Friday, June 26th. Finally, Daiwa Securities Group boosted their price objective on Johnson & Johnson from $237.00 to $246.00 and gave the company an “outperform” rating in a research note on Thursday, April 16th. Twenty analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $261.26.
View Our Latest Research Report on Johnson & Johnson
Key Johnson & Johnson News
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: Royal Bank of Canada raised its price target on Johnson & Johnson (JNJ) to $287 from $265 and kept an outperform rating, implying additional upside as investors look ahead to earnings. Benzinga
- Positive Sentiment: Several market watchers highlighted JNJ as a potential buy before earnings, pointing to its strong year-to-date move, recent all-time highs, and the appeal of its dividend as capital rotates into healthcare names. The Real Case for Buying Johnson & Johnson (JNJ) Before July 15
- Positive Sentiment: Analysts and stock commentary remain focused on JNJ’s upcoming quarterly results, with expectations centered on continued operational strength despite patent and competitive headwinds. Zacks: Is JNJ Stock a Buy, Sell or Hold Ahead of Q2 Earnings Release?
- Neutral Sentiment: Broader market weakness weighed on Wall Street Monday, which could limit gains even for defensive names like JNJ. NASDAQ Snaps 3-Day Winning Streak as Oil Jumps Amid US-Iran Tensions
- Neutral Sentiment: Pre-earnings previews from Zacks, TipRanks, and Barron’s kept Johnson & Johnson in focus, but these pieces were mainly commentary ahead of the report rather than new company-specific catalysts. Zacks: Is Johnson & Johnson Stock Poised for New Highs as Q2 Results Approach?
Johnson & Johnson Company Profile
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
